奥美医疗(002950) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥814,642,103.91, a decrease of 17.96% compared to ¥993,038,858.37 in the same period last year[5] - Net profit attributable to shareholders was ¥127,884,816.36, down 18.92% from ¥157,718,066.54 year-on-year[5] - Basic and diluted earnings per share were both ¥0.2019, representing an 18.95% decrease from ¥0.2491 in the same period last year[5] - Net profit for Q1 2023 was CNY 126,903,850.28, a decline of 20.1% from CNY 158,868,668.14 in Q1 2022[15] - Total operating revenue for Q1 2023 was CNY 814,642,103.91, a decrease of 18.0% compared to CNY 993,038,858.37 in the same period last year[14] Cash Flow - The net cash flow from operating activities was negative at -¥18,723,058.99, a decline of 105.66% compared to ¥330,956,749.48 in the previous year[5] - The net cash flow from operating activities for Q1 2023 was -18,723,058.99 CNY, a significant decrease compared to 330,956,749.48 CNY in the same period last year[16] - Total cash inflow from operating activities was 940,419,306.34 CNY, down from 1,202,779,163.11 CNY year-over-year[16] - Cash outflow from operating activities totaled 959,142,365.33 CNY, compared to 871,822,413.63 CNY in Q1 2022, indicating increased operational expenses[16] - The net cash flow from investing activities was -20,245,035.02 CNY, an improvement from -618,958,416.84 CNY in the previous year[16] - The net cash flow from financing activities was -181,235,250.55 CNY, a decline from 65,683,837.33 CNY in Q1 2022[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,408,683,142.95, down 5.90% from ¥5,747,507,000.10 at the end of the previous year[5] - Total liabilities for Q1 2023 were CNY 2,174,097,125.85, down from CNY 2,616,522,450.63 in the previous period[13] Shareholder Information - The total number of common shareholders at the end of the reporting period was 46,810[9] - The largest shareholder, Cui Jinhai, holds 23.02% of the shares, followed by Cheng Hong with 15.14%[9] - Shareholders' equity attributable to the parent company increased by 3.37% to ¥3,205,653,161.46 from ¥3,101,070,727.75[5] - The total equity attributable to shareholders of the parent company was CNY 3,205,653,161.46, an increase from CNY 3,101,070,727.75 year-over-year[13] Expenses - Total operating costs for Q1 2023 were CNY 678,212,282.59, down 17.6% from CNY 822,936,104.86 year-over-year[14] - Research and development expenses for Q1 2023 were CNY 21,823,941.49, up 26.5% from CNY 17,272,408.39 in the same period last year[14] - The company reported a decrease in financial expenses, with a net financial cost of CNY -4,424,766.26 compared to CNY -99,815.56 in the previous year[14] - Other comprehensive income for Q1 2023 was CNY -23,302,382.65, compared to CNY -4,712,888.11 in the same period last year[15] Audit Status - The company’s first quarter report was not audited[18]